Author:
Suárez C.,Puente J.,Gallardo E.,Méndez-Vidal M. J.,Climent M. A.,León L.,Olmos D.,García del Muro X.,González-Billalabeitia E.,Grande E.,Bellmunt J.,Mellado B.,Maroto P.,González del Alba A.
Publisher
Springer Science and Business Media LLC
Reference156 articles.
1. Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014). Cancer statistics, 2014. CA: A Cancer Journal for Clinicians. doi: 10.3322/caac.21208 .
2. James, N. D., Spears, M. R., Clarke, N. W., Dearnaley, D. P., De Bono, J. S., Gale, J., et al. (2014). Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: data from 917 patients in the control arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). European Urology. doi: 10.1016/j.eururo.2014.09.032 .
3. Klotz, L., Miller, K., Crawford, E. D., Shore, N., Tombal, B., Karup, C., et al. (2014). Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists. European Urology, 66, 1101–1108. doi: 10.1016/j.eururo.2013.12.063 .
4. Crawford, E. D., Shore, N. D., Moul, J. W., Tombal, B., Schröder, F. H., Miller, K., et al. (2014). Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix. Urology, 83, 1122–1128. doi: 10.1016/j.urology.2014.01.013 .
5. Garcia-Albeniz, X., Chan, J. M., Paciorek, A. T., Logan, R. W., Kenfield, S. A., Cooperberg, R. M., et al. (2014). Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. Journal of Clinical Oncology, 32, 5s (suppl; abstr 5003).
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献